Dr Li on the Investigation of BDC-1001 in HER2-expressing So

Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid Tumors

Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.


Related Keywords

China , Bobt Li , , Bobst International Center , Memorial Sloan Kettering Cancer Center , Thoracic Liquid Biopsy Program ,

© 2025 Vimarsana